Flow Forward is developing a novel approach to rapidly establish high-quality vascular access sites for hemodialysis. The Arteriovenous Fistula Eligibility (AFE) System™ is a small, temporary, external blood pump designed to stimulate flow-mediated dilation to make more patients eligible for an arteriovenous fistula (AVF), and increase success rates after surgery. Establishment of a reliable AVF reduces morbidity and mortality in hemodialysis patients, as well as the overall cost of care.

Nonclinical data shows the AFE System can dilate veins 20 times faster than with a traditional AVF, with a dramatic reduction in the formation of internal hyperplasia (vascular scarring). Flow Forward expects that widespread use of the AFE System would allow the rapid establishment of high-quality AVFs in nearly all hemodialysis patients.